Clinical trials: Pemphigus Vulgaris
Pemphigus Vulgaris
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active…
- Trial name
- NCT02383589
- Testing
- Mycophenolate Mofetil, Rituximab
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Pemphigus
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and…
- Trial name
- NCT00283712
- Testing
- Infliximab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus Vulgaris
Comparing DCP and DAP for Pemphigus Vulgaris
What's the study about? This study focused on comparing two different treatments for pemphigus vulgaris, a skin condition caused when body's immune system works against itself.
- Trial name
- DCP;DAP (NCT06846255)
- Testing
- Dexamethasone Cyclophosphamide Pulse therapy, Dexamethasone Azathioprine Pulse therapy
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Pemphigus Disease, Pemphigus Vulgaris (PV)
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Pemphigus is characterized by the presence of IgG antibodies that lead to the loss of keratinocyte adhesion, resulting in blister formation.
- Trial name
- NCT06663943
- Testing
- CM313 (SC), Glucocorticoids
- Volunteers
- 100 people
- Sponsor
- Chao Ji
Pemphigus Vulgaris
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue…
- Trial name
- NCT02704429
- Testing
- PRN1008
- Where
- 13 sites in Australia, Croatia and 3 more
- Volunteers
- 42 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Pemphigus Vulgaris (PV), Periodontal Diseases
Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients
The aim of this study is to evaluate the relationship between the severity of Pemphigus Vulgaris (a chronic autoimmune skin disease) and periodontal (gum) health, and to compare the findings with those of a systemically healthy…
- Trial name
- NCT07384221
- Testing
- Clinical Periodontal and Oral Evaluation
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Pemphigus Vulgaris
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
The objective of this retrospective study was to investigate the factors influencing in-hospital relapse during acute episodes of pemphigus, an autoimmune blistering disease characterized by self-antibodies targeting desmogleins.
- Trial name
- NCT06167408
- Where
- China
- Volunteers
- 96 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Pemphigus
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who…
- Trial name
- NCT02613910
- Testing
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline